Treatment of inappropriate sinus tachycardia with ivabradine

Martino Annamaria, Pier Paolo Lupo, Sara Foresti, Guido de Ambroggi, Ermenegildo de Ruvo, Luigi Sciarra, Riccardo Cappato, Leonardo Calo

Research output: Contribution to journalArticlepeer-review


Background: Inappropriate sinus tachycardia (IST) often causes palpitations, dyspnea, and exercise intolerance, that are generally treated with beta blockers and non-dihydropyridine calcium-channel antagonists. Ivabradine, a selective inhibitor of cardiac pacemaker If current, has recently emerged as an effective and safe alternative to conventional drugs for IST. Methods: We performed a systematic overview of clinical studies on the therapeutic yield of ivabradine in patients with inappropriate sinus tachycardia, published in MEDLINE database from January 2000 to March 2015. Results: Overall, five case reports were found, all showing efficacy of ivabradine in subjects affected by IST. Eight non-randomized clinical studies demonstrated short- and medium-term safety and efficacy of ivabradine administration in IST, also in adjunction to or in comparison with metoprolol. One double-blind randomized crossover study also showed that ivabradine is superior to placebo for heart rate (HR) reduction and symptoms control in patients affected by IST. Conclusions: Ivabradine is effective and safe in short- and medium-term treatment of IST. However, long-term follow-up studies and randomized studies comparing ivabradine with beta blockers are still lacking.

Original languageEnglish
JournalJournal of Interventional Cardiac Electrophysiology
Publication statusAccepted/In press - Oct 14 2015


  • Inappropriate sinus tachycardia
  • Ivabradine
  • Tachy-cardiomyopathy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)


Dive into the research topics of 'Treatment of inappropriate sinus tachycardia with ivabradine'. Together they form a unique fingerprint.

Cite this